Conference Description

Registration closed for this course!>p> April 26, 2008
Westin Fort Lauderdale
400 Corporate Drive
Ft. Lauderdale, FL
954-772-1331

Tell a friend about this conference

Download the brochure for this conference

Release Date: April 26, 2008

Expiration Date: April 26, 2008

Estimated Time To Complete CME Activity: 3.75 Hours

Medium/Method: Live Conference

Hardware/Software Requirements: None

CME Credits: 4.0* Category I PRA; 3.75 Prescribed credits by AAFP

Nonrefundable registration fee: $0.

Target Audience: Gastroenterologists and Primary Care Providers.

Program Summary:

This educational activity is designed to provide Gastroenterologists, primary care physicians, nurse practitioners, physician assistants and other primary care providers interested in treating gastrointestinal diseases the opportunity to learn about current treatments for Hepatitis B & C, management of refractory GERD, different treatment options for treating Inflammatory Bowel Disease, diagnosis and management of cancer dysplasia in patients with IBD, and treatments for Non-Ulcer Dsyspepsia (NUD).

In planning this CME activity, the National Association for Continuing Education (NACE) performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance. Learning objectives (see below), linked to identified gaps were developed and will be addressed by each presenter.

This multidisciplinary program will utilize a variety of educational techniques incorporating the various aspects of Adult Learning Principles. There will be emphasis on audience participation utilizing interactive case-based presentations to deliver educational material. Participants will be asked to engage in pre and post testing to collect data for outcome studies and to uncover unmet needs for future programming.

Each participant will be provided with a syllabus containing presentations, clinical tools, and practical guidelines at the start of the program to be used for future reference.

Learning Objectives:
At the conclusion of this program, participants should be able to:

1. list the current treatment recommendations for Hepatitis B & C
2. discuss new treatments for Hepatitis B and C that are on the horizon
3. explain how to anticipate and manage the complications of Hepatitis therapy
4. explain how we can be sure the symptoms we assume are GERD are from GERD
5. discuss the state of the art tests to confirm GERD
6. discuss therapies to manage the truly resistant GERD
7. discuss when to use the biologics and how to choose among them in the treatment of inflammatory bowel disease
8. recognize risks and benefits of NSAIDs, ASA, and Cox-2 Inhibitors
9. explain when to stop the 6MP
10. discuss if the mesalamine agents still have a role in the treatment of inflammatory bowel disease
11. review the use of steroids in treating inflammatory bowel disease
12. explain when and and how often colonoscopic screening should be done in the IBD patient
13. be able to interpret the diagnosis of dysplasia from the pathologist
14. discuss counseling the patient with dysplasia – when to follow, when to operate
15. discuss counseling the patient with dysplasia – when to follow, when to operate
16. evaluate the role of H. pylori in NUD
17. discuss the role of motor disorder in NUD

Agenda:
Saturday, April 26, 2008

7:15-8:00 am		Registration and Continental Breakfast
8:00-8:10		Welcome Matthew Soff, MD and Herbert Cohen,MD
8:10-8:55		Hepatitis B&C: What is our current treatment and where are we going? Christopher O'Brien, MD
8:55-9:40		Refractory GERD: PPI’s and beyond, what do we do about those really tough cases? Howard Manten, MD
9:40-9:55		Break
9:55-10:40		Inflammatory Bowel Disease: Making sense of the increasing number of treatment options Gary R. Lichtenstein, MD
10:40-11:25		Diagnosis and management of cancer and dysplasia in patients with IBD Gary R. Lichtenstein, MD
11:25-11:40		Break
11:40-12:25		Non-Ulcer Dyspepsia (NUD): Is it bugs, muscles or brains? Matthew Soff, MD
12:25-12:30		Conference Wrap Up Matthew Soff, MD and Herbert Cohen, MD

Faculty:
Gary R. Lichtenstein, MD
Professor of Medicine
University of Pennsylvania School of Medicine
Director, Center for Inflammatory Bowel Disease
Hospital of the University of Pennsylvania
Philadelphia, PA

Howard D. Manten, MD
Associate Professor of Medicine and Pediatrics
University of Miami School of Medicine
Chief of Gastroenterology
Miami VA Medical Center

Christopher O’Brien, MD
Professor of Medicine
Miller School of Medicine
University of Miami
Miami, FL

Matthew Soff, MD
Community Gastroenterologist
Plantation, FL

Program Chairs: Matthew Soff, MD and Herbert Cohen, MD

Activity Director: Michelle Frisch, MPH

*Continuing Education Information
This activity has been reviewed and is acceptable for up to 3.75 Prescribed credit(s) by the American Academy of Family Physicians. The AAFP invites comments on any activity that has been approved for AAFP CME credit. Please forward your comments on the quality of this activity to cmecomment@aafp.org.

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS) and the National Association for Continuing Education. The University of Massachusetts Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Massachusetts Medical School designates this educational activity for a maximum of 4.0 AMA PRA Category I Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Under the auspices of the University of Massachusetts Medical School Office of Continuing Education this offering meets the requirements for 4.8 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244-CMR 5.04). Each nurse should claim only those hours of credit that he/she actually spend in the educational activity.

Policy on Faculty and Provider Disclosure: It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials..

This program was supported through educational grants from the following companies: Elsai, GILEAD, TAP, Wyeth.